Compare RENT & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | ANIX |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6M | 114.0M |
| IPO Year | 2021 | 2013 |
| Metric | RENT | ANIX |
|---|---|---|
| Price | $1.77 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 194.7K | ★ 365.4K |
| Earning Date | 04-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.16 | 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $329,800,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.71 | N/A |
| 52 Week Low | $1.72 | $2.32 |
| 52 Week High | $10.13 | $5.46 |
| Indicator | RENT | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 24.28 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $3.79 | N/A |
| Average True Range (ATR) | 0.33 | 0.00 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 5.50 | 0.00 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.